Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Ishida T, et al. Among authors: ito s. J Clin Oncol. 2016 Dec;34(34):4086-4093. doi: 10.1200/JCO.2016.67.7732. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621400 Clinical Trial.
Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
Akagi T, Takahashi N, Yamaguchi K, Ishizawa K, Murai K, Tajima K, Ikeda K, Kameoka Y, Kameoka J, Ito S, Kato Y, Noji H, Shichishima T, Itoh J, Ichinohasama R, Harigae H, Ishida Y, Sawada K. Akagi T, et al. Among authors: ito s. J Clin Exp Hematop. 2011;51(1):29-35. doi: 10.3960/jslrt.51.29. J Clin Exp Hematop. 2011. PMID: 21628858 Free article.
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y. Murai K, et al. Among authors: ito s. Eur J Haematol. 2015 Dec;95(6):558-65. doi: 10.1111/ejh.12536. Epub 2015 Mar 25. Eur J Haematol. 2015. PMID: 25703064 Clinical Trial.
Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.
Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H; Tohoku Hematology Forum. Yokoyama H, et al. Among authors: ito t, ito s. Int J Hematol. 2017 May;105(5):606-613. doi: 10.1007/s12185-017-2190-8. Epub 2017 Feb 7. Int J Hematol. 2017. PMID: 28176226
Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma.
Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, Ito S, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Takahashi N. Kameoka Y, et al. Among authors: ito s. Int J Hematol. 2018 Nov;108(5):510-515. doi: 10.1007/s12185-018-2508-1. Epub 2018 Jul 24. Int J Hematol. 2018. PMID: 30043334 Clinical Trial.
Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.
Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K; for collaborative Investigators. Imaizumi Y, et al. Among authors: ito s. Cancer Sci. 2020 Dec;111(12):4567-4580. doi: 10.1111/cas.14658. Epub 2020 Oct 21. Cancer Sci. 2020. PMID: 32976684 Free PMC article.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.
Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K. Ishida T, et al. Among authors: ito s. Jpn J Clin Oncol. 2022 Dec 5;52(12):1446-1449. doi: 10.1093/jjco/hyac137. Jpn J Clin Oncol. 2022. PMID: 36073950 Free PMC article. Clinical Trial. No abstract available.
9,460 results